News
Kelun's Merck & Co.-partnered ADC scores late-stage win in front-line PD-L1-negative NSCLC
2+ hour, 6+ min ago (19+ words) FirstWord Pharma...
Spero shifts to immunology, inflammation via $1.1B licensing deal with Innovent
1+ day, 8+ hour ago (13+ words) FirstWord Pharma...
AstraZeneca turns to China again, this time for Sino Biopharm's experimental respiratory drug
1+ week, 5+ hour ago (15+ words) FirstWord Pharma...
Pharvaris moves closer to bringing second oral on-demand HAE therapy to US
1+ week, 2+ day ago (15+ words) FirstWord Pharma...
Roche inks $490M+ breast cancer therapeutics deal with Otsuka's Astex
1+ week, 2+ day ago (12+ words) FirstWord Pharma...
Novartis snaps up UK ADC developer Myricx in $1.5B deal
1+ week, 2+ day ago (12+ words) FirstWord Pharma...
UK regulator expands use of Novo Nordisk's Wegovy into MASH
1+ week, 5+ day ago (11+ words) Semaglutide (Wegovy) approved to treat form of liver disease FirstWord Pharma...
Pan-cancer AI tool boosts immunotherapy prediction accuracy
1+ week, 5+ day ago (10+ words) FirstWord Pharma...
Friday Five – Top-line takeaways, Medicare bridges GLP-1 coverage gap, Ipsen's specialty deal duo…and more
1+ week, 5+ day ago (19+ words) FirstWord Pharma...
Biopharma bites: Otsuka's long-term Voyxact data, United takes out Thymmune, and more from Junshi, Novartis, Arcturus
1+ week, 5+ day ago (19+ words) FirstWord Pharma...